Date: 2012-10-25
Type of information: Development agreement
Compound: companion diagnostics paired with novel Bayer HealthCare drugs
Company: Bayer (Germany) Qiagen (The Netherlands)
Therapeutic area: Cancer - Oncology
Type agreement: development
commercialisation
Action mechanism:
Disease: cancer, various solid tumours
Details: Qiagen and Bayer HealthCare have announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.
The companies have indicated that this agreement also lays the groundwork for a strong partnership in creating future companion diagnostics both inside and outside of oncology.
Financial terms: Financial details were not disclosed.
Latest news:
